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ABSTRACT 
Breast cancer is a highly heterogeneous disease. The efficacy of tailored therapeutic strategies relies 
on the precise detection of diagnostic biomarkers by immunohistochemistry (IHC). Therefore, 
considering the increasing incidence of breast cancer cases, a concomitantly time-efficient and 
accurate diagnosis is clinically highly relevant. 
Microfluidics is a promising innovative technology in the field of tissue diagnostic, enabling for rapid, 
reliable and automated immunostaining. We previously reported the microfluidic-based HER2 (human 
epidermal growth factor receptor 2) detection in breast carcinomas to greatly correlate with the HER2 
gene amplification level. 
Here, we aimed to develop a panel of microfluidic-based IHC protocols for prognostic and therapeutic 
markers routinely assessed for breast cancer diagnosis, namely HER2, estrogen/progesterone 
receptor (ER/PR) and Ki67 proliferation factor. 
The microfluidic IHC protocol for each marker was optimized to reach high staining quality comparable 
to the standard procedure, while concomitantly shortening the staining time to 16 minutes - excluding 
deparaffinization and antigen retrieval step - with a turnaround time reduction up to 7 folds. 
Comparison of the diagnostic score on 50 formaldehyde-fixed paraffin-embedded breast tumor 
resections by microfluidic versus standard staining showed high concordance (overall agreement: 
HER2 94%, ER 95.6%, PR 93.6%, Ki67 93.7%) and strong correlation (ρ coefficient: ER 0.89, PR 0.88, 
ki67 0.87; p<0.0001) for all the analyzed markers. Importantly, HER2 genetic reflex test for all 
discordant cases confirmed the scores obtained by the microfluidic technique.  
Overall, the microfluidic-based IHC represents a clinically validated equivalent approach to the 
standard chromogenic staining for rapid, accurate and automated breast cancer diagnosis. 
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INTRODUCTION 
Breast cancer is the most commonly diagnosed tumor and leading cause of cancer death in women 
world-wide [1], accounting for almost one quarter of female cancer cases [2].  
In combination with histological evaluation of standard hematoxylin-eosin staining, 
immunohistochemistry (IHC) of formaldehyde-fixed paraffin-embedded (FFPE) tissue biopsies has 
become an essential tool in oncologic pathology to guide personalized clinical management of 
patients. To analyze any putative breast cancer tissue, the expression of prognostic and therapeutic 
markers is routinely assessed, including the human epidermal growth factor receptor 2 (HER2), 
estrogen receptor (ER), progesterone receptor (PR) and proliferation factor Ki67 [3]–[5]. The efficacy 
of the therapeutic strategies relies on the precise detection and quantification of these diagnostic 
markers. Therefore, considering the increasing incidence of breast cancer cases, a concomitantly time-
efficient and accurate assessment of biomarkers on tumor samples is of high clinical relevance. 
Recently, we developed a microfluidic tissue processor (MTP) device and used to perform IHC and 
immunofluorescence (IF) staining on FFPE and frozen histological samples [6]–[8]. The microfluidic-
based device is a pressure-driven system that allows reagents to be delivered on a biological sample 
via the fast-fluidic exchange (FFEX) technology, enabling for a precisely controlled immune-reaction 
to take place in an extremely short incubation time. In fact, the microfluidic IHC staining on frozen 
samples lasts less than 12 minutes [8]. Furthermore, the employment of the microfluidic-based device 
resulted in a better repartition of HER2 positive/negative breast carcinoma cases, thus reducing the 
number of equivocal HER2 scores by 90% and allowing for HER2 gene copy number prediction [6], [7]. 
Here, we aimed to develop and validate a panel of microfluidic IHC protocols for the breast cancer 
diagnostic markers HER2, ER, PR and Ki67. To this purpose, we performed a comparative clinical study 
using 50 successive eligible FFPE breast cancer resections to assess whether (i) the clinical diagnostic 
score and (ii) analytical performance achieved by the microfluidic staining device were equivalent to 
a routinely used BenchMark ULTRA automated stainer. 
  
MATERIAL and METHODS 
Breast cancer tissues 
A total of 50 FFPE breast tumor resections retrieved from the files of Pathology Institute of the 
University Hospital of Lausanne (CHUV) were included in this study (ethical committee approval 
protocol number 511-12). Successive eligible cases were collected from January 2016 without any pre-
selection criteria for biomarkers grading. Tissue specimens were anonymized before being stained and 
blindly scored by a pathologist. The standard IHC and FISH assay were repeated for the purpose of the 
study, rather than reanalyzing the slides prepared during the diagnostic procedure. 
Tissue slide pre-processing for MTP-based IHC  
Tissue sections were dried for 10 minutes at 65°C, dewaxed for 10 minutes 30 seconds in Histoclear 
(National Diagnostic, HS200) and rehydrated by consecutive washes in ethanol: 100% for 30 seconds, 
100%, 95%, 70% and 40% vol/vol for 10 seconds and then placed in MilliQ water. Heat-induced antigen 
retrieval was performed at 95°C for 40 minutes at pH6 (Dako, pH6, S1699) for CK and Ki67 staining, 
and at pH9 (Dako, pH9, S2367) for ER, HER2 and PR staining. After cooling down to room temperature 
for 20 minutes, the samples were transferred in TBS before being placed on the microfluidic device. 
Microfluidic-based IHC staining  
The microfluidic device prototype used in this study was designed and manufactured by Lunaphore 
Technologies SA. The principle of operation of the microfluidic device employed for the IHC stainings 
is described in Fig. 1a. Optimized incubation time for all protocol step and primary antibody dilutions 
for the MTP-device are reported in Fig. 1b. MTP-based stainings were preformed using custom-made 
HRP-conjugated secondary antibodies and DAB chromogenic substrates. Counterstaining was 
performed with 20% Hematoxylin solution (Thermo Scientific, Gill3, 72604) in MilliQ water. All 
protocol steps were performed at 37°C. 
Primary antibodies 
The primary antibody used in the study are as follows: mouse anti-human cytokeratin (CK) clone 
AE1/AE3 (Dako M3515, 1.07 mg/L); mouse anti-human ER clone 6F11 (Novocastra NCL-L-ER-6F11, 
1.50 mg/L); rabbit anti-human HER2 clone 4B5 (Ventana 709-2991, ready to use); mouse anti-human 
Ki67 clone MIB-1 (Dako M7240, 0.92 mg/L); mouse anti-human PR clone PgR-636 (Dako M3569, 0.81 
mg/L). Primary antibodies were diluted in TBS 0.1% Tween (Fisher Bio-Reagents, BP337); working 
dilutions are reported in Fig. 1b. Same primary antibody batches were used both for standard and 
MTP-based stainings. The alternative primary antibody clones used for ER and PR standard staining on 
discordant cases were rabbit anti-human ER clone SP1 (Ventana 790-4325, ready to use) and PR clone 
1E2 (Ventana 790-4296, ready to use). 
Standard IHC pre-processing and staining 
Standard IHC assays were performed on a BenchMark ULTRA automated stainer (Roche Ventana) 
according to manufacturer recommendations. Detailed protocols are provided in Suppl. Material and 
Methods. 
Tissue slide IHC post-processing and image acquisition 
The stained slides were rinsed with MilliQ water and dehydrated in ethanol 95% - ethanol absolute 
(Reactolab SA, 99570) – xylol (VWR Chemicals, 28973.363) baths (3x5 seconds each step). The slides 
were then mounted with Glas Mounting Medium (Sakura, Tissue-Tek, 1408) and coverslip 24x50 mm 
(VWR, ECN 631-1574) by using Tissue-Tek Glas g2-E2 (Sakura Finetek, 6502). The images were acquired 
with the digital slide scanner NanoZoomer S60 (Hamamatsu, C13210-01) and visualized with the Leica 
Biosystems Version 4.0.7 (Leica Biosystems). 
IHC quality parameters, diagnostic scoring and exclusion criteria 
The quality of IHC staining was evaluated on each slide, as perceived by an experienced pathologist, 
based on the following parameters: intensity, background, specificity, contrast, sharpness, 
morphology and counterstaining. Intensity and sharpness were not evaluated in negative-scored 
samples. For each parameter a mark from 1 (insufficient) to 5 (excellent) was assigned.  
CK was scored in a binary way as positive or negative. The diagnostic scores for ER/PR, HER2 and Ki67 
were evaluated according to 2010 ASCO/CAP guideline [9], 2013  ASCO/CAP guideline [10] and 2015 
St. Gallen Conference recommendations [11], respectively. Detailed IHC quality and scoring 
parameters are provided in Suppl. Material and Methods. 
Negative cases without internal positive control were considered technically unsatisfactory and 
discarded from the analysis (ER n=1, Ki67 n=1). Tissue sections that were ruined during the pre- or 
post-staining procedure resulting in unreadable stained cases were also excluded from the scoring 
comparison (CK n=1, PR n=3, Ki67 n=1). All excluded cases are shown as strikethrough boxes in Suppl. 
Table 1. 
Discordant scores 
The diagnostic score was considered to be discordant when being inversely classified by the two 
employed staining techniques as positive/negative for ER and PR (cut-off 1% positive tumor nuclei), 
or high/low for Ki67 (cut-off 15% positive tumor nuclei). HER2 status was considered discordant when 
differently classified as negative, equivocal or positive according to the scoring criteria defined above. 
HER2 discordant cases (n=3) were further analyzed by FISH reflex test, according to the 2013 
ASCO/CAP guideline recommendations [10]. Discordant cases for ER (n=2), PR (n=5) and Ki67 (n=8) 
were blindly reviewed by a pathologist. For ER and PR, the cases remained discordant after rescoring 
where stained with an alternative primary antibody clone by the standard automated stainer; 
however, the resulting score was not used to redefine the overall agreement or correlation coefficient. 
Discordant diagnostic score values are shown in bold case in Suppl. Table 1. 
Dual-probe HER2/CEP17 FISH 
FISH assay was performed as previously reported [12] using the HER2/CEP17 dual-labeled DNA probe 
(PathVysion HER2 DNA Probe Kit, Abbott Molecular). Images were acquired using the Zeiss fluorescent 
microscope at high resolution (63x objective, 1.4 numerical aperture). Results were interpreted 
according to 2013 ASCO/CAP recommendations [10].  
RESULTS 
Optimization of the IHC protocol for microfluidic-based staining of breast cancer diagnostic markers  
The microfluidic device is an automated pressure-driven system allowing for fast and uniform delivery 
of reagents on the tissue section, thus resulting in a precisely controlled immune-reaction within an 
extremely short incubation time enabled by the fast-fluidic exchange technology (Fig. 1a). 
Microfluidic IHC for pan-cytokeratin (CK), commonly used to identify tumor epithelial cells, was firstly 
developed as a positive control marker on FFPE breast carcinoma cases (Suppl. Fig. S1). Microfluidic 
staining protocol for the diagnostic markers HER2, ER, PR and Ki67 was subsequently optimized to 
reach a detection level comparable to the reference staining obtained from a routinely used standard 
automated stainer (Suppl. Fig. S2). In parallel, a negative control was performed by using the same 
staining protocols without adding the primary antibody. The obtained stainings displayed the absence 
of chromogenic signal and adequate counterstaining (Suppl. Fig. S2 and S3). The optimized staining 
conditions for all markers assessed in this study are reported in Fig. 1b, in comparison to routinely 
used standard protocols. Staining time for the optimized microfluidic protocol was shortened to 16 
minutes, resulting in 5 to 7 folds decrease in time with respect to the BenchMark ULTRA protocols 
(Fig. 1b) – not including the tissue section deparaffinization and antigen retrieval pre-processing steps. 
Reproducibility of the microfluidic-based IHC 
To assess the reproducibility of the IHC protocol performed on the microfluidic device, a day-to-day 
repeatability test was run on three different days (with unchanged operator and location) for (i) CK 
using 3 different breast carcinomas - in parallel with negative controls without primary antibody 
(Suppl. Fig. S4a), and (ii) HER2, PR and Ki67 on two different tissues (Suppl. Fig. S4b). The multiple IHC 
assays performed on different days resulted in comparable pattern of expression and quality of 
staining on all tissue replicates for the assessed markers. Furthermore, to evaluate the consistency of 
the microfluidic staining for diagnostic purposes, the HER2, PR and Ki-67 stained tissues were clinically 
scored.  HER2 score for both samples (0 and 3+) was identical on the three replicates; one sample 
triplicates showed equal score for PR (80%) and Ki67 (10-15%), while the other sample varying score 
(PR: 100-95-95%; Ki67: 40-35-30%), with a standard deviation of 3 (coefficient of variation, CV: 0.03) 
and 5% (CV: 0.14), respectively.  
Analytical and Diagnostic Performance Comparison  
To assess the clinical reliability of the stainings performed by the microfluidic device, 50 FFPE surgically 
resected invasive breast carcinoma specimens were stained for CK, HER2, ER, PR, Ki67 and 
subsequently scored for both analytical and diagnostic performance, in comparison to a standard 
automated stainer routinely used in tumor diagnostics (Fig. 1c). The optimized protocols, as defined 
in the above paragraph, were employed for the microfluidic-based assays. The brown tone of the 
microfluidic staining shifted towards a reddish brown, whereas the standard staining towards brown-
black, possibly due to the usage of the copper sulfate signal enhancer on the BenchMark-stained 
samples. Yet, the developed microfluidic protocol achieved high qualitative performance equivalent 
to the routine assay for all assessed markers (Suppl. Fig. S5).  
As expected for breast carcinomas, all stained samples with both the MTP and BenchMark devices 
were cytokeratin positive (Suppl. Table 1).  
HER2. Employment of the microfluidic device resulted in a high-quality HER2 staining 
comparable to the standard assay (Fig. 2a-b) for all considered parameters as shown in Suppl. Fig. S5. 
Staining results for HER2 IHC were evaluated according to the 2013 ASCO/CAP guideline 
recommendations, with HER2 status being classified as positive (3+ score), equivocal (2+ score) or 
negative (1+ and 0 score). Comparison of HER2 diagnostic score for microfluidic-based versus standard 
staining assay showed an overall agreement of 94%, with 47 cases (35 negative, 9 equivocal and 3 
positive) out of 50 concordantly classified by the two techniques (Fig. 2c and Suppl. S6a). One of the 
3 discordant cases was classified negative (1+) by the standard staining and equivocal (2+) by the 
microfluidic staining; vice versa, the other two discordant cases were classified equivocal (2+) by the 
routine assay and negative (1+) by the MTP-based assay (Fig. 2d and Suppl. Table 1). FISH analysis 
confirmed the HER2 status to be concordant with the scoring assessed by the microfluidic staining 
assay for all 3 analyzed cases (Fig. 2d and Suppl. Table 1). As recommended by the ASCO/CAP 
guidelines, all 8 cases concordantly scored as equivocal by both IHC techniques were also analyzed via 
FISH assay (one case was not assessed due to lack of biological material). Six cases were confirmed to 
be HER2 equivocal by FISH analysis, one was HER2 amplified and one was HER2 negative (Suppl. Fig. 
S6b). 
ER. The microfluidic-based assay showed a high qualitative ER staining performance 
comparable to the standard staining (Fig. 3a-b) for all considered parameters (Suppl. Fig. S5). 
Evaluation of the ER positive/negative status (cut-off: 1% positive tumor nuclei) for the microfluidic-
based versus standard staining techniques showed an overall agreement of 95.9%, with 47 out of 49 
concordantly scored cases (Fig. 3c and Suppl. Table 1). Two out of 49 specimens were differently 
classified for ER status using the two staining techniques: ER-negative (both 0%) by standard staining 
and ER-positive (2 and 20%) by MTP staining (Fig. 3c). The microfluidic-based staining detected a 
higher percentage of ER positive nuclei in samples with low to moderate positivity by standard assay. 
Nevertheless, pairwise comparison of the assessed percentage of positive tumor nuclei employing the 
two staining techniques resulted in a strong positive correlation with a Pearson coefficient (ρ) equal 
to 0.89 (p-value < 0.0001).  
PR. The MTP-based assay showed a high qualitative PR staining performance comparable to 
routine methodology as shown in Fig. 4a-b and Suppl. Fig. S5.  Evaluation of the PR positive/negative 
status (cut-off: 1% positive tumor nuclei) as assessed by the microfluidic versus standard assay showed 
an overall agreement of 93.6%, with 3 out of 47 cases being discordantly classified (Fig. 4c and Suppl. 
Table 1). The 3 discordant case were classified as PR-negative (all scored 0%) after standard IHC while 
PR-positive (one case 3% and two cases 5%) after microfluidic-based assay (Fig. 4c). The MTP-based 
PR staining, although using four times less concentrated (1:100) primary antibody than the BenchMark 
(1:25), resulted in higher percentage of PR positive nuclei in samples displaying low to moderate 
positivity by standard assay. Nonetheless, pairwise comparison of the scored percentage of positive 
tumor nuclei resulting from two assays showed a strong positive correlation with a Pearson coefficient 
(ρ) equal to 0.88 (p-value < 0.0001).  
Ki67. The MTP-based immunoreaction resulted in a high qualitative Ki67 staining performance 
(Fig. 5a) equivalent to the standard assay (Suppl. Fig. S5). The Ki67 proliferative index was computed 
as the percentage of positive tumor cell nuclei (Fig. 5b), as it is regularly evaluated as a continuum 
value for clinical decisions contingently to its intended use. Pairwise comparison of the percentage of 
Ki67-stained tumor nuclei as assessed by two IHC techniques resulted in a strong positive correlation 
with a Pearson coefficient (ρ) equal to 0.87 (p-value < 0.0001). For Ki67 score dichotomization as 
high/low, it was defined a data-derived cut-off point of 15% Ki67-positive nuclei, corresponding to the 
sample population median value as per standard assay; an equal median value resulted from the 
microfluidic-stained population. Three cases out of 48 were differentially classified as Ki67 high/low 
with an overall agreement of 93.7%. All 3 discordant cases were classified as Ki67-low (score 10%) by 
standard assay, while Ki67-high (one case 20% and two 15%) by microfluidic-based IHC (Suppl. Table 
1). 
 
DISCUSSION 
In this study we proved the clinical validity of the microfluidic-based IHC assay as an equivalent 
approach to the standard chromogenic staining, allowing for breast cancer diagnosis by automated, 
rapid and accurate detection of HER2, ER, PR and Ki67. 
Immunohistochemistry is a fundamental methodology in the diagnostic process of solid tumors. The 
need for IHC is constantly intensifying due to increasing cancer incidence and higher number of 
biomarker assessments per patient, according to recent trends in personalized medicine. The 
instruments commonly used for IHC on clinical specimen require hours to perform the staining 
process. Employment of the microfluidic tissue processor device allowed to perform IHC staining of 
breast cancer biopsies in less than 16 minutes - apart from deparaffinization and antigen retrieval step 
- with a time reduction down to 7 folds. A turnaround time lower than the state-of-the-art techniques 
opens the possibility of obtaining higher throughputs in clinical laboratories, reducing the congestion 
in healthcare systems.  
The configuration of the microfluidic device prototype, at the time of this study, required a reagent 
volume double as compared to the standard automated stainer, resulting in economic disadvantage 
other conditions being equal. However, this was in part counterbalanced by the lower concentration 
of the primary antibody used in the microfluidic device protocols, e.g. down to four times less for PR. 
Moreover, the next generation of the microfluidic device includes improvements for reducing the 
reagent consumption to be leastwise comparable to the standard techniques.  
The HER2 microfluidic staining in breast carcinoma was previously reported to better correlate with 
the HER2 gene amplification status as assessed by FISH [6], [7]. Consistently with prior observations, 
all discordant cases were confirmed to be correctly classified by MTP staining when re-analyzed by 
FISH assay, both for lower (1+ versus 2+) and higher (2+ versus 1+) HER2 scored samples.  
Being the primary aim of the study to prove the equivalency of the microfluidic IHC to the standard 
assay in a real clinical setting, the specimens were collected from a hospital diagnostic facility as 
chronologically accessible. Of note, the distribution of the cases across the scoring categories was 
unbalanced with a small proportion of HER2-positive carcinomas (i.e. 3/50 cases), providing limited 
statistical power in consideration of individual categories; however this was inherent to the design of 
the study and reflected the biomarker distribution in the actual population. 
Stratification of HER2-negative results by the assigned score, 0 or 1+, showed about half of the cases 
(15/35) differentially scored by the two IHC assays, with most of the cases (13/15) scored as 1+ by the 
MTP while 0 by standard HER2 staining. In a similar manner, the MTP staining could detect a higher 
number of ER and PR positive nuclei in samples showing low to moderate percentage of positivity by 
standard assay, being for PR even more remarkable due to four times lower primary antibody 
concentration in the MTP staining. These data suggested for the microfluidic device to enable for 
higher sensitivity as compared to the standard assay.  This feature could partially account for the ER 
and PR discordantly scored samples, which were in all cases classified as negative by BenchMark while 
positive by MTP device. Among others, sensitivity and specificity of different primary antibodies clones 
are important parameters for IHC accuracy [9], [13]. The anti-human ER rabbit monoclonal SP1 
antibody was previously reported to exert a greater sensitivity compared with other clones, including 
6F11 [13]. Standard IHC assay of the ER discordant cases with the SP1 clone confirmed one case to be 
positive as assessed by MTP, while the other one remained negative (data not shown). In previous 
studies, the anti-human PR rabbit monoclonal 1E2 antibody showed higher analytical affinity for PR 
with respect to the 636 clone [13], [14]. Standard staining of PR discordant cases with the 1E2 clone 
confirmed two of the three cases to be positive as assessed by microfluidic assay, while one remained 
negative as by standard staining (data not shown). Remarkably, the two cases reassessed with the 1E2 
clone as positive, showed the same percentage of positive nuclei as for the MTP-based assay (5% for 
both samples). Keeping the detection system fixed for the standard assay when performing the 
staining with a different primary antibody clone, ruled out the possibility that apparently higher 
sensitivity was due to the employment of different detection system for the two assays. The ER/PR 
positivity after standard staining with alternative clones suggested for higher sensitivity of the MTP 
that could be counter-balanced by supposedly more sensitive primary antibodies for the standard 
assay. Unlike for HER2, there is no accepted alternative assay for assessing ER and PR status for 
discordant cases [13]; therefore, the score resulting from alternative clones was not used to redefine 
the agreement or concordance. Higher sensitivity of the microfluidic device could represent a high 
added value with potential economic and health benefits, e.g. false negative proportion for hormone 
receptor ER/PR status in breast cancer was reported to be 20-30% [15]. Testing of such a possibility 
will require further investigation on a validation set enriched in low-expression and negative samples 
to be correlated with clinical outcome. The three Ki67 discordant cases were classified as high by the 
MTP while low by standard assay; however, in this case there was not a trend for higher Ki67 
percentage detected by the microfluidic device in the analyzed sample population. 
Semi-quantitative measurement of HER2, ER/PR and Ki67 is relevant for IHC-based surrogate subtype 
classification of breast cancer in HER2-positive, luminal A-/B-like or triple negative for prognosis and 
therapeutic strategy determination. According to the latest criteria proposed by Prat et al. [16] and 
accepted in the 13th St Gallen International Breast Cancer Conference [17], one case would be 
discordantly subtyped as luminal B versus A and two cases as luminal A versus B according to PR (cut-
off 20%) and Ki67 (cut-off 14%) status as determined by standard or microfluidic assay, respectively.  
Overall, here we proved the rapidity and non-inferiority of the microfluidic IHC with respect to 
standard assay for breast cancer diagnosis. Furthermore, being the microfluidic device an open-
system, it represents an effective tool for validation and clinical use of any current and emerging 
biomarkers for tissue diagnostics.
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FIGURE LEGENDS 
Figure 1 Schematic representation of microfluidic tissue processor (MTP) device, optimized 
protocols and clinical study design (a) The MTP device is based an automated pressurized system 
allowing for rapid and uniform sequential delivery of reagents in a reaction chamber. The chamber of 
reaction (100 μm in height) is created at the interface between a microfluidic chip (MTP) and the glass 
slide carrying the tissue sample. This open-system allows the allocation of any suitable reagents either 
in four different 50 ml reservoirs (e.g. buffers) or in eight 1.5-2 ml reservoirs (e.g. antibodies). Reagents 
are dispensed and washed out by a pressure-driven flow via the microtubing system which is 
connected to the reagent delivery system (RDS) component. Reagents flow through the MTP system 
to reach the reaction chamber where the immunological reaction takes place. The exchange of 
reagents is done in a timeframe of 1 second due to the fast-fluidic exchange (FFEX) technology, which 
allows the immune-reaction to occur in an extremely short incubation time. After the incubation, the 
reagents were collected in the waste tube. (b) Microfluidic IHC staining protocols for CK, HER2, ER, PR 
and Ki67 on FFPE breast cancer resections. Optimized incubation time for all protocol step and primary 
antibody dilutions are shown as compared to routinely used standard (STD) protocols. H2O2: oxygen 
peroxidase; AbI/II: primary/secondary antibody; DAB: 3, 3'-diaminobenzidine; CuSO4: copper sulfate; 
HTX: hematoxylin. (c) Clinical study workflow. 
 
Figure 2 HER2 staining comparison (a-b) Shown is a representative breast carcinoma (a) HER2 positive 
(score 3+) and (a) HER2 negative (score 0) by standard (upper panels) or MTP-based (bottom panels) 
IHC assay. Scale bar: 1 mm, 100 µm and 10 µm (left to right). (c) HER2 IHC scoring table. Shown are 
concordantly scored cases (highlighted in grey) by MTP and standard assay: 35 negative (0-1+), 9 
equivocal (2+) and 3 positive (3+); discordantly scored cases are in blue. (d) HER2 scoring comparison: 
IHC versus FISH. Shown is HER2 scoring by standard (STD), microfluidic (MTP) and dual probe 
(HER2/CEP17) FISH assay for the 3 discordant cases in (c); highlighted in grey are HER2 concordantly 
scored cases by MTP and FISH assay. The HER2 diagnostic score values for all cases arranged by 
chronological order (1-50) are reported in Suppl. Table 1. 
 
Figure 3 ER staining comparison (a-b) Shown is a representative breast carcinoma (a) ER positive (90% 
positive nuclei) and (b) ER negative by standard (upper panels) or MTP-based (bottom panels) IHC 
assay. Scale bar: 1 mm, 100 µm and 10 µm (left to right). (c) ER scoring comparison. Shown is the 
percentage of ER positive tumor cell nuclei as assessed by a standard or microfluidic (MTP) assay on 
evaluable cases (n=49); cases are arranged by increasing ER scoring as per standard assay. The ER 
diagnostic score values for all cases arranged by chronological order (1-50) are reported in Suppl. 
Table 1.  
 
Figure 4 PR staining comparison (a) Shown is a representative breast carcinoma positive for PR by 
standard (upper panels, 60% positive nuclei) or MTP-based (bottom panels, 40% positive nuclei) IHC 
assay. Scale bar: 1 mm, 100 µm and 10 µm (left to right). (b) Shown is a representative breast 
carcinoma negative for PR by standard (upper panels) or MTP-based (bottom panels) IHC assay. Scale 
bar: 1 mm, 100 µm and 10 µm (left to right). (c) PR scoring comparison. Shown is the percentage of 
PR positive tumor cell nuclei as assessed by standard or microfluidic (MTP) assay on evaluable cases 
(n=47); cases are arranged by increasing PR scoring as per standard assay. The PR diagnostic score 
values for all cases arranged by chronological order (1-50) are reported in Suppl. Table 1. 
 
Figure 5 Ki67 staining comparison (a) Shown is a representative breast carcinoma stained for KI67 
(90% positive nuclei) by standard (upper panels) or MTP-based (bottom panels) IHC assay. Scale bar: 
1 mm, 100 µm and 10 µm (left to right). (b) Ki67 scoring comparison. Shown is the percentage of Ki67 
positive tumor cell nuclei as assessed by standard or microfluidic (MTP) assay on FFPE breast 
carcinoma (n=48); cases are arranged by increasing Ki67 scoring by standard assay. The Ki67 diagnostic 
score values for all cases arranged by chronological order (1-50) are reported in Suppl. Table 1. 
Figure 1 
 
 
Marker (Clone) CK (AE1/AE3) HER2 (4B5) ER (6F11) PR (PgR-636) Ki67 (MIB-1) 
Staining Device STD MTP STD MTP STD MTP STD MTP STD MTP 
AbI Dilution 1:100 1:67 RTU  RTU 1:50 1:50 1:25 1:100 1:50 1:50 
P
ro
to
c
o
l 
S
te
p
s
 H2O2 4  4  4  4  4  
AbI 32 4 16 4 32 4 32 4 32 4 
AbII 8 4 8 4 8 4 8 4 8 4 
DAB 8 2.5 8 2.5 8 2.5 8 2.5 8 2.5 
CuSO4 4  4  4  4  4  
HTX 8 0.25 8 0.25 12 0.25 8 0.25 4 0.25 
Total Time (min) 102 16 84 16 114 16 114 16 102 16 
  
a c 
b 
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Supplementary Figure S1 CK staining comparison Shown is a representative breast carcinoma 
stained for CK by standard (upper panels) or MTP-based (bottom panels) IHC assay. Scale bar: 1 mm, 
100 µm and 10 µm (left to right). The CK status – as expected classified as positive (score 1) for all 
carcinoma cases – is reported in Suppl. Table 1. 
  
 Supplementary Figure S2 Breast cancer diagnostic markers panel Representative IHC staining for 
ER, PR, HER2, Ki67 and CK (left to right). Shown are negative controls (CTL NEG) obtained by the 
microfluidic (MTP) staining protocol without use of the primary antibody (first row) and IHC staining of 
each marker by using the MTP-device (second row) or standard (STD) benchmark machine (third row) 
used as a reference (CTL POS). Scale bar 50 µm.  
 
  
MTP  
STD  
 Supplementary Figure S3 Microfluidic negative controls. Representative negative controls obtained 
by running the staining protocols without the primary antibody using either anti-mouse (upper panels) 
or anti-rabbit (lower panels) secondary antibodies. Scale bar: 1 mm, 100 µm and 10 µm (left to right). 
      
 
 
 
  
Day#1 Day#2 Day#3 Day#1 Day#2 Day#3 
CK Negative Control 
Case#A 
      
Case#B 
      
Case#C 
      
 
 
Day#1 Day#2 Day#3 Day#1 Day#2 Day#3 
Case#D Case#E 
HER2 
      
Score: 0 Score: 0 Score: 0 Score: 3+ Score: 3+ Score: 3+ 
PR 
      
Score: 100% Score: 95%  Score: 95% Score: 80% Score: 80% Score: 80% 
Ki67 
      
Score: 40% Score: 35% Score: 30% Score: 10-15% Score: 10-15% Score: 10-15% 
 
Supplementary Figure S4 Reproducibility of the microfluidic-based IHC Shown are representative 
images of microfluidic IHC for (a) CK and the negative control without primary antibody on three cases 
(#A-B-C) or (b) HER2 (upper), PR (middle) and Ki67 (bottom) on two cases (#D-E) performed on three 
different days (#1-2-3). The HER2, PR and Ki67 diagnostic score is shown below each image. Scale 
bar: 50 µm. 
b 
a 
  
 
Supplementary Figure S5 Analytical performance comparison All tissue slides stained by the 
standard or microfluidic (MTP) device for CK, HER2, ER, PR and Ki67 were evaluated for the staining 
quality based on the following parameters: intensity, background, specificity, contrast, sharpness, 
morphology and counterstaining. For each parameter a mark from 1 (insufficient) to 5 (excellent) was 
assigned; mean ± s.e.m. 
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STD IHC 
Score 
MTP IHC 
Score 
FISH 
Score 
HER2 
Copy 
CEP17 
Copy 
HER2/CEP17 
Ratio 
Nr of Scored 
Nuclei 
2+ 2+ Equivocal 5.08 3.43 1.48 40 
2+ 2+ Equivocal 4.3 2.95 1.46 40 
1+ 2+ Equivocal 4.1 3.2 1.28 40 
2+ 2+ Equivocal 4.9 3.05 1.61 40 
2+ 2+ Equivocal 4.7 3.53 1.33 80 
2+ 2+ Negative 3.89 3.28 1.19 80 
2+ 1+ Negative 3.91 2.69 1.46 80 
2+ 1+ Negative 3.88 2.61 1.48 80 
2+ 2+ NA -- -- -- -- 
2+ 2+ Positive 5.57 2.57 2.17 60 
2+ 2+ Equivocal 5.26 3.06 1.72 80 
2+ 2+ Equivocal 5.81 3.14 1.85 80 
Supplementary Figure S6 Detailed HER2 cross-methodology scoring comparison (a) HER2 IHC 
scoring table. Shown are concordantly scored cases (highlighted in grey) by MTP and standard assay: 
35 negative (0-1+), 9 ambiguous (2+, in red) and 3 positive (3+); 3 discordantly scored cases are in 
blue. (b) HER2 scoring comparison: IHC versus FISH. Shown is HER2 scoring by standard (STD), 
microfluidic (MTP) and dual probe (HER2/CEP17) FISH assay for 3 discordant cases (blue) and 8 
concordant ambiguous cases (red). Raw values for HER2/CEP17 copy number and ratio are reported. 
Total number of scored nuclei is reported in the last column.  
  
HER2 Scoring 
Standard IHC 
0 1+ 2+ 3+ 
M
T
P
 I
H
C
 0 11 2 0 0 
1+ 13 9 2 0 
2+ 0 1 9 0 
3+ 0 0 0 3 
a 
b 
 CK HER2 ER PR Ki67 
Case STD MTP STD MTP STD MTP STD MTP STD MTP 
#1 1 1 0 1+ 90 90 40 90 20 15 
#2 1 1 0 1+ 30 60 5 30 30 20 
#3 1 1 0 0 0 0 0 0 80 50 
#4 1 1 3+ 3+ 0 0 0 0 60 25 
#5 1 1 0 0 80 90 90 90 20 20 
#6 1 1 0 0 95 100 70 70 25 15 
#7 1 1 0 0 15 50 0 0 30 25 
#8 1 1 1+ 1+ 90 90 1 20 20 20 
#9 1 1 0 1+ 100 90 0 0 1 1 
#10 1 1 0 0 80 80 90 80 25 15 
#11 1 1 0 1+ 100 90 5 60 20 20 
#12 1 1 2+ 2+ 80 80 60 50 20 15 
#13 1 1 2+ 2+ 90 90 10 2 10 20 
#14 1 1 1+ 2+ 70 30 80 80 10 5 
#15 1 1 2+ 2+ 70 80 90 80 5 5 
#16 1 1 1+ 1+ 80 85 60 40   
#17 1 1 3+ 3+ 30 70 10 20 5 5 
#18 1 1 0 0 70 80 1 3 5 5 
#19 1 1 1+ 0 0 20 100 100 10 15 
#20 1 1 0 1+ 0 0 0 3 40 60 
#21 1 1 0 0 0 2 0 0 90 90 
#22 1 1 1+ 1+ 60 80 100 100 40 40 
#23 1 1 2+ 2+ 90 100 3 10 15 20 
#24 1 1 0 0 90 100 70 80 20 20 
#25 1 1 0 1+   0 0 15 15 
#26 1 1 0 0 80 80 60 80 15 20 
#27 1 1 1+ 1+ 90 100 20 20 30 30 
#28 1 1 0 1+ 40 40 80 60 10 3 
#29 1 1 1+ 1+ 80 80 0 0 1 1 
#30 1 1 2+ 2+ 80 100 0 0 5 5 
#31 1 1 0 1+ 50 90 50 90 10 15 
#32 1 1 2+ 1+ 90 80 0 5 30 30 
#33   0 0 80 80   5 10 
#34 1 1 2+ 1+ 90 100     
#35 1 1 0 1+ 0 0 0 0 15 15 
#36 1 1 2+ 2+ 80 90   15 15 
#37 1 1 3+ 3+ 50 80 20 30 10 10 
#38 1 1 1+ 0 90 90 20 20 25 30 
#39 1 1 1+ 1+ 90 100 80 90 5 3 
#40 1 1 2+ 2+ 70 90 2 10 10 10 
#41 1 1 1+ 1+ 50 90 60 50 25 15 
#42 1 1 2+ 2+ 90 90 20 40 30 15 
#43 1 1 0 1+ 60 90 30 50 10 5 
#44 1 1 2+ 2+ 100 100 40 100 20 30 
#45 1 1 1+ 1+ 20 30 0 5 15 20 
#46 1 1 0 1+ 90 100 5 5 15 20 
#47 1 1 0 1+ 90 100 70 100 5 10 
#48 1 1 0 0 60 40 20 30 20 30 
#49 1 1 1+ 1+ 70 90 15 30 5 5 
#50 1 1 0 1+ 100 100 40 70 5 10 
 
Supplementary Table 1. Shown are diagnostic score values for all markers as assessed by standard 
(STD) or microfluidic (MTP) assay on FFPE breast carcinomas arranged by chronological order (case 
#1-50). CK (0: negative, 1: positive); HER2 (0-1+: negative, 2+: equivocal, 3+: positive); ER and PR 
positive tumor nuclei percentage (<1% negative, ≥1% positive); Ki67 positive tumor nuclei percentage 
(<15% low, ≥15% high). Strikethrough boxes are cases excluded during the scoring process according 
to the exclusion criteria as described in the materials and methods section. Discordantly scored samples 
are in bold case. 
Supplementary M&M 
Standard IHC pre-processing and staining 
Standard IHC assays were performed on a BenchMark ULTRA automated stainer (Roche Ventana) 
according to manufacturer recommendations. The sample was initially heated up for 4 minutes at 
72°C and placed in EZ prep solution (Roche Ventana, 950-102) for deparaffinization. Heat-induced 
antigen retrieval was performed at 95°C in Cell Conditioning Solution 1 (CC1, Roche Ventana, 950-124) 
for 8 (PR staining) or 30 minutes (CK, ER, HER2 and Ki67 staining). Incubation time for all staining steps 
and primary antibody dilutions are reported in Fig. 1b. The ultraView Universal DAB detection kit 
(Roche Ventana, 760-900) was used as detection system. Tissue counterstaining was performed with 
Hematoxylin solution (Millipore, 75290; 1:1 with acetic acid 100% in double MilliQ water volume). All 
staining steps were performed at 36°C. Staining for ER and PR with alternative primary antibody clones 
on discordantly scored cases were performed on the BenchMark as detailed in Fig. 1b, except for 
primary antibody and hematoxylin incubation lasting 16 and 8 minutes, respectively. 
IHC quality parameters  
The quality of IHC staining was evaluated based on the following parameters: intensity (level of 
detected signal in the target structures); background (non-specific staining); specificity (absence of 
unexpected reactivity); contrast (blurry, diffuse or monochromatic staining not allowing distinction of 
tissue structures); sharpness (absence of overstaining allowing clear visualization of the target 
protein); morphology (adequacy of tissue morphology); counterstaining (clear visualization of tissue 
structures). 
IHC diagnostic scoring 
ER, PR and HER2 were evaluated according to ASCO/CAP guideline recommendations [1], [2].  
ER and PR were considered positive when >1 % of the tumor cells showed a nuclear staining. The 
intensity of the staining was also evaluated as faint, moderate or strong.  
HER2 staining was considered negative (score 0), when no staining or membrane staining that was 
incomplete and faint/barely perceptible was seen in <10% of tumor cells. HER2 was interpreted as 
negative (score 1+), if incomplete membrane staining that was faint/barely perceptible and within > 
10% of tumor cells was present. In case of an incomplete and/or weak/moderate circumferential 
membrane staining within > 10% of tumor cells or an intense complete and circumferential membrane 
staining and within <10% of tumor cells, it was scored as equivocal (score 2+). Cases considered 
positive (score 3+) were those showing complete and intense circumferential membrane staining 
within >10% of tumor cells. For equivocal cases, a reflex HER2 FISH test was performed.  
The Ki67 (MIB-1) index represents the percentage of positively staining cells among the total number 
of invasive cells in the scored area. At least 3 high-power (×40 objective) fields, including hot spots if 
present, were evaluated. Only nuclear staining was considered positive and the staining intensity was 
not considered relevant for the Ki67 index. Each case was reported as Ki67-high when displaying at 
least 15% of positive tumor cell nuclei, and Ki67-low when less than 15%; the cut-off point of 15% was 
a data-derived threshold, corresponding to the sample population median value in accordance with 
the 2015 St. Gallen Conference recommendations [3].  
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